The physicians on the staff of Mount Sinai Urology Associates are fellowship-educated clinicians and researchers who are leaders in advancing emerging diagnostic techniques and treatments for kidney cancer. Our approach is multidisciplinary. We partner with our distinguished colleagues in the Department of Radiation Oncology, the Department of Medicine, and at Mount Sinai’s Tisch Cancer Institute to ensure we are providing comprehensive, personalized, and coordinated treatment.
A hallmark of Mount Sinai Urology Associates is that we encourage the active involvement of our patients. We spend time discussing the benefits and risks associated of each procedure and treatment option, and encourage our patients to become as knowledgeable as possible so that the conversation can be truly two-way.
Mount Sinai is conducting a Phase III clinical trial for a personalized kidney cancer vaccine. Learn more about the advanced kidney cancer study